Lv11
30 积分 2024-04-23 加入
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
2小时前
待确认
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
11天前
已完结
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
1个月前
已完结
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
2个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2个月前
已完结
Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC
2个月前
已完结
EGFR TKI combination with immunotherapy in non-small cell lung cancer
2个月前
已完结
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
3个月前
已完结
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors
3个月前
已完结
Case 20-2023: A 52-Year-Old Man with a Solitary Fibrous Tumor and Hypoglycemia
3个月前
已完结
皖公网安备34019202002308
